Related Experiment Video
Updated: Jan 29, 2026

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
Published on: March 29, 2024
Alogliptin for the treatment of Type 2 diabetes
1a Kansai Elect Power Hosp, 2-1-7 Fukushima-ku, Osaka, 553-0003 Japan.
Abstract:
Type 2 diabetes mellitus is a chronic progressive disease, and over time patients often need to be treated with more than one type of antidiabetic agent in order to maintain control of blood glucose levels. Dipeptidyl peptidase-4 inhibitors are one of the newer classes of antidiabetic drugs used in the treatment of diabetes. These oral incretin-based therapies are effective at improving glycemic control, have a low risk of hypoglycemia, are weight neutral, and can be administered in combination with other antidiabetic agents. This article summarizes the pharmacological and pharmacokinetic properties of alogliptin, a dipeptidyl peptidase-4 inhibitor, and also evaluates its clinical efficacy, safety and tolerability in the treatment of patients with Type 2 diabetes.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Psychoneuroimmunology: Diabetes and Cancer
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H

